Login Register Cart 0
Perspective

蛋白酶体作为锥虫病的药物靶标

卷 24, 期 10, 2023

发表于: 20 July, 2023

页: [781 - 789] 页: 9

弟呕挨: 10.2174/1389450124666230719104147

摘要

由锥虫寄生虫引起的一些疾病，如利什曼病、南美锥虫病和非洲人类锥虫病 (HTA)，管理起来很困难，主要涉及药物治疗，因为它们与弱势群体有关。不幸的是，在寻找新药方面缺乏大量投资。因此，帮助发现新药的策略之一是识别和抑制对寄生虫生存至关重要的分子靶点，例如蛋白酶体，它可以降解寄生虫细胞中的大多数蛋白质。我们的研究提出了几种具有不同药效核心的蛋白酶体抑制剂，其中两种，5和13，在利什曼病治疗的临床阶段表现突出。

关键词: 锥虫，被忽视的热带病，利什曼病，恰加斯病，昏睡病，HTA。

« Previous Next »
[1]
Leishmaniasis, World Heal. Organ 2022.
[2]
Burza S, Croft SL, Boelaert M. Leishmaniasis. Lancet 2018; 392(10151): 951-70.
[http://dx.doi.org/10.1016/S0140-6736(18)31204-2] [PMID: 30126638]
[3]
WHO. Chagas disease (American trypanosomiasis), World Heal Organ 2022.
[4]
Chatelain E. Chagas disease drug discovery: Toward a new era. SLAS Discov 2015; 20(1): 22-35.
[http://dx.doi.org/10.1177/1087057114550585] [PMID: 25245987]
[5]
Lopes RD, Gimpelewicz C, McMurray JJV. Chagas disease: Still a neglected emergency? Lancet 2020; 395(10230): 1113-4.
[http://dx.doi.org/10.1016/S0140-6736(20)30171-9] [PMID: 32247391]
[6]
Sutherland CS, Yukich J, Goeree R, Tediosi F. A literature review of economic evaluations for a neglected tropical disease: Human African trypanosomiasis (“sleeping sickness”). PLoS Negl Trop Dis 2015; 9(2): e0003397.
[http://dx.doi.org/10.1371/journal.pntd.0003397] [PMID: 25654605]
[7]
Du X, Hansell E, Engel JC, Caffrey CR, Cohen FE, McKerrow JH. Aryl ureas represent a new class of anti-trypanosomal agents. Chem Biol 2000; 7(9): 733-42.
[http://dx.doi.org/10.1016/S1074-5521(00)00018-1] [PMID: 10980453]
[8]
Büscher P, Cecchi G, Jamonneau V, Priotto G. Human African trypanosomiasis. Lancet 2017; 390(10110): 2397-409.
[http://dx.doi.org/10.1016/S0140-6736(17)31510-6] [PMID: 28673422]
[9]
WHO. Model lists of essential medicines, world heal. Organ 2022.
[10]
Pedrique B, Strub-Wourgaft N, Some C, et al. The drug and vaccine landscape for neglected diseases (2000–11): A systematic assessment. Lancet Glob Health 2013; 1(6): e371-9.
[http://dx.doi.org/10.1016/S2214-109X(13)70078-0] [PMID: 25104602]
[11]
Bijlmakers MJ. Ubiquitination and the proteasome as drug targets in trypanosomatid diseases. Front Chem 2021; 8: 630888.
[http://dx.doi.org/10.3389/fchem.2020.630888] [PMID: 33732684]
[12]
Burge RJ, Damianou A, Wilkinson AJ, Rodenko B, Mottram JC. Leishmania differentiation requires ubiquitin conjugation mediated by a UBC2-UEV1 E2 complex. PLoS Pathog 2020; 16(10): e1008784.
[http://dx.doi.org/10.1371/journal.ppat.1008784] [PMID: 33108402]
[13]
Khare S, Nagle AS, Biggart A, et al. Proteasome inhibition for treatment of leishmaniasis, chagas disease and sleeping sickness. Nature 2016; 537(7619): 229-33.
[http://dx.doi.org/10.1038/nature19339] [PMID: 27501246]
[14]
Nagle A, Biggart A, Be C, et al. Discovery and characterization of clinical candidate lxe408 as a kinetoplastid-selective proteasome inhibitor for the treatment of leishmaniases. J Med Chem 2020; 63(19): 10773-81.
[http://dx.doi.org/10.1021/acs.jmedchem.0c00499] [PMID: 32667203]
[15]
Wyllie S, Brand S, Thomas M, et al. Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition. Proc Natl Acad Sci 2019; 116(19): 9318-23.
[http://dx.doi.org/10.1073/pnas.1820175116] [PMID: 30962368]
[16]
Thomas M, Brand S, De Rycker M, et al. Scaffold-hopping strategy on a series of proteasome inhibitors led to a preclinical candidate for the treatment of visceral leishmaniasis. J Med Chem 2021; 64(9): 5905-30.
[http://dx.doi.org/10.1021/acs.jmedchem.1c00047] [PMID: 33904304]
[17]
Zmuda F, Sastry L, Shepherd SM, et al. Identification of novel trypanosoma cruzi proteasome inhibitors using a luminescence-based high-throughput screening assay. Antimicrob Agents Chemother 2019; 63(9): e00309-19.
[http://dx.doi.org/10.1128/AAC.00309-19] [PMID: 31307977]
[18]
Nagendar P, Gillespie JR, Herbst ZM, et al. Triazolopyrimidines and imidazopyridines: Structure–activity relationships and in vivo efficacy for trypanosomiasis. ACS Med Chem Lett 2019; 10(1): 105-10.
[http://dx.doi.org/10.1021/acsmedchemlett.8b00498] [PMID: 30655955]
[19]
Tatipaka HB, Gillespie JR, Chatterjee AK, et al. Substituted 2-phenylimidazopyridines: A new class of drug leads for human African trypanosomiasis. J Med Chem 2014; 57(3): 828-35.
[http://dx.doi.org/10.1021/jm401178t] [PMID: 24354316]
[20]
Lima ML, Tulloch LB, Corpas-Lopez V, et al. Identification of a proteasome-targeting arylsulfonamide with potential for the treatment of chagas’ disease. Antimicrob Agents Chemother 2022; 66(1): e01535-21.
[http://dx.doi.org/10.1128/AAC.01535-21] [PMID: 34606338]

Rights & Permissions Print Cite
Article Metrics
33
2
© 2024 Bentham Science Publishers | Privacy Policy